- Opinion
- [Reporter's View] Innovation exists in treating all diseases
- by Eo, Yun-Ho Aug 20, 2025 06:23am
- When discussing Korea’s insurance reimbursement system, the qualifier “life-threatening” has long been a source of frustration. It is no exaggeration to say that, for the pharmaceutical industry, this phrase has been the number one target for removal since the very beginning. This was the case in determining eligibility for the Risk Sh
- Opinion
- [Reporter's View] Clarify support for unstable supply drugs
- by Lee, Hye-Kyung Aug 19, 2025 06:11am
- The Ministry of Food and Drug Safety is reportedly preparing support measures to stabilize the supply of national essential medicines and other items with unstable supply. The MFDS initially announced its intention to specify the urgent measures required by the industry to stabilize supply, such as emergency imports, custom manufacturing, an
- Opinion
- [Reporter's View] Sales dilemma of newly listed bioventures
- by Whang, byung-woo Aug 12, 2025 06:15am
- &160;“Off to a fair start” was the market’s assessment regarding the stock prices and performance of biotech companies that went public on the KOSDAQ this year. However, upon closer inspection, some point out that the strengthened scrutiny of financial figures following the Fadu incident (accounting and revenue recognition controvers
- Opinion
- [Reporter's View] Can NA resolve the drug shortage issue?
- by Kim, Jin-Gu Aug 6, 2025 06:09am
- Whether the four bills presented for amendments to the Pharmaceutical Affairs Act aimed at resolving the shortage of medicines will be discussed at the National Assembly's Health and Welfare Committee in August is gaining attention. The amendments to the Pharmaceutical Affairs Act were proposed by Rep. Jeong-ae Han, Rep. Yoon Kim, and Rep
- Opinion
- [Reporter's View] KRPIA opts for 'maintain' over 'change'
- by Eo, Yun-Ho Aug 1, 2025 06:15am
- The Korea Research-based Pharma Industry Association (KRPIA) has chosen continuity over change. The KRPIA recently confirmed the appointment of Vice Chairman Lee Young-shin (68) to the position of Executive Vice Chairman, who is currently leading the association. This decision was made after amending the articles of incorporation to addres
- Opinion
- [Reporter’s View] AI-assisted diagnosis and its hurdles
- by Whang, byung-woo Jul 28, 2025 06:08am
- Advanced technologies such as AI-assisted diagnosis and robotic surgery are being actively introduced into the domestic medical field more than ever before. Robotic surgery, which was first introduced 20 years ago, has now become the standard treatment in many fields. For example, the Da Vinci Robotic Surgical System, introduced in 2005,
- Opinion
- [Reporter's View] Denmark's corporate model, Wegovy success
- by Jul 25, 2025 06:10am
- I recently had the opportunity to visit the biotech industry in Denmark. I toured facilities like Novo Nordisk, which rose to stardom with its GLP-1-based obesity treatment Wegovy, as well as LEO Pharma, with its 117-year history, and Lundbeck, a powerhouse in the central nervous system field. What struck me was that all these companies, wit
- Opinion
- [Reporter's View] Bio policy should remain consistent
- by Kim, Jin-Gu Jul 17, 2025 06:13am
- In November 2024, the Yoon Suk Yeol government officially announced the launch of the National Bio Committee. The government aimed to operate a 'presidential' governance body in a preparatory response to the global bioeconomy era. Considering that the previously established 'Bio-health Innovative Committee' was chaired by the Prime Minister,
- Opinion
- [Reporter's View] Gov’t cooperation leads to a price cut?
- by Eo, Yun-Ho Jul 16, 2025 06:10am
- There are times when cooperation ends up causing losses. In an ironic twist, pharmaceutical companies that participated in the government's infertility support program have now found their products caught in the net of the Price-Volume Agreement (PVA) system, leaving them little choice but to face rapid drug price cuts. The government's i
- Opinion
- [Reporter’s View]Biotech’s responsible approach to failure
- by Cha, Jihyun Jul 15, 2025 06:06am
- Cases of terminated licensing deals and halted clinical trials are on the rise in Korea's biotech sector. Recently, IntoCell announced that the licensing agreement for its ADC (antibody-drug conjugate) platform with ABL Bio had been canceled due to patent overlap issues. Prior to that, Orum Therapeutics voluntarily decided to halt clinical d
